Breast Cancer Care comments on new treatment for advanced HER2-positive breast cancer patients as Perjeta (pertuzumab) gets regulatory green light.

Dr Emma Pennery Clinical Director of Breast Cancer Care said:

“Patients with HER2-positive advanced breast cancer and their families will welcome today’s news that Perjeta (pertuzumab) has been approved for use in the UK.

“This drug when combined with Herceptin and chemotherapy can provide a more effective targeted treatment option to delay progression of this aggressive disease than Herceptin and chemotherapy alone but with comparable side effects.

“The priority now must be that Perjeta is made widely accessible across the UK as soon as possible for patients with secondary breast cancer whose lives could be extended from its use.”

Ends
For further media information please contact:
Sophie Howells 0207 960 3450/ Sophie Softley Pierce
0207 960 3505 sophie.howells@breastcancercare.org.uk/sophie.pierce@breastcancercare.org.uk

For more information about how we can support people living with secondary breast cancer visit breastcancernow.org or call our free confidential expert helpline on 0808 800 6000.

About Breast Cancer Care
When breast cancer and its treatment overshadow everything we see the woman underneath. Breast Cancer Care is the only UK-wide charity dedicated to providing emotional and practical support for anyone affected. Our free helpline information-packed website and online forums offer a friendly ear and expert information to those dealing with this life-threatening disease. Across the UK we offer a range of confidential face-to-face services for people living with and beyond breast cancer. We campaign for better support and care and promote the importance of early detection involving people with breast cancer in all that we do. Visit breastcancernow.org or call our free helpline on 0808 800 6000.